Last reviewed · How we verify

NCT07149701

Ventricular Tachycardia Cohort

Not yet recruiting Last updated 2 September 2025
What this trial tests

trial testing Intervention in Ventricular Tachycardia (VT) in 1,500 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
1 September 2029
1 December 2029

Quick facts

Lead sponsorBeijing Anzhen Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment1,500
Start date1 September 2025
Primary completion1 September 2029
Estimated completion1 December 2029

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Anzhen Hospital

Who can join

Eligibility, any sex, with Ventricular Tachycardia (VT). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to detect the long-term risk of a composite endpoint event in adult patients with ventricular tachycardia (VT) who are managed with catheter ablation or non-ablation management (including modern drug therapy and/or ICD therapy).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Ventricular Tachycardia (VT)

Currently open trials in the same condition.

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07149701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing